2020-003173-22
A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD)
F. Hoffmann-La Roche Ltd·EU Clinical Trials Register
Study focus
- Disease/Condition
- Autism Spectrum Disorder
Sponsor & location
- Primary sponsor
- F. Hoffmann-La Roche Ltd
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
1. Change From Baseline in Vineland-II Adaptive Behavior Scale Two Domain Composite (2DC) Score at Week 24
ICD-10 classifications
Childhood autismAtypical autismAsperger syndromeNeurotic disorder, unspecifiedMental and behavioural disorders
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2020-003173-22
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2020-003173-22 through Pure Global AI's free database. This phase not specified trial is sponsored by F. Hoffmann-La Roche Ltd and is currently status unknown. The study focuses on Autism Spectrum Disorder.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.